Julie E. Bauman, MD, MPH, and Sharad Goyal, MD, were among 100 physicians and researchers selected as the 2025 recipients of the Fellow of the American Society of Clinical Oncology (FASCO) designation. FASCO status is one of ASCO’s highest honors and a lifetime designation, recognizing members who have sustained extraordinary volunteer service, engagement, and leadership within the organization.
The FASCO designation honors individuals who have made long-term contributions to the broader oncology community through involvement in ASCO committees, publications, policy development, and mentorship. Fellows serve as ambassadors for the society, helping to shape programs, influence policy, and support workforce development on a global scale.
In a statement announcing this year’s cohort of fellows, ASCO said, “The 100 individuals honored in 2025 embody the critical link between clinical excellence and professional service. Their collective work reinforces ASCO’s global influence through mentorship, guideline development, educational leadership, and patient-centered advocacy.”
Bauman, who serves as the Dr. Cyrus Katzen Family Director of the George Washington University (GW) Cancer Center, associate dean of cancer at the GW School of Medicine and Health Sciences (SMHS), and professor of medicine, joined the faculty at GW in 2022. Bauman is widely recognized for her work in developmental therapeutics for both cancer prevention and treatment.
In cancer therapeutics, she leads multiple national studies for patients with head and neck cancer as well as clinical trials testing new immunotherapies for patients with solid tumors. Her prevention research focuses on “green chemoprevention,” evaluating plants or their simple extracts to enhance carcinogen detoxification.
Bauman serves as the MPI of the University of Arizona Cancer Prevention Clinical Trials Network, one of four NCI-funded networks performing early phase cancer prevention studies. She also is the Deputy PI for NRG Oncology’s NCORP Research Base, which designs and performs phase II and III cancer prevention and control studies.
“I am so honored to be recognized as a Fellow of the American Society of Clinical Oncology, the premier global society for oncology professionals,” said Bauman. “Reflecting upon 20 years of service, I wish to recognize ASCO as the organization that keeps me connected and inspired to change the face of cancer in our lifetime. At the GW Cancer Center, we resonate with ASCO’s mission, ‘Conquering cancer through research, education, and promotion of the highest quality patient care,’ as we work toward a cancer-free world for all, in D.C. and beyond.”
An internationally recognized radiation oncologist and researcher with a focus on breast cancer, Goyal serves as the Division Director of Radiation Oncology at the GW Cancer Center. In July 2025, he was installed as the inaugural Luther W. Brady Professor of Radiation Oncology. Also a Fellow of the American Society for Radiation Oncology, Goyal has authored more than 140 peer-reviewed publications and serves on multiple editorial boards and national committees related to oncologic imaging, health policy, and clinical guidelines.
“I am incredibly honored to be named a Fellow of the American Society of Clinical Oncology," said Goyal. “Throughout my life, I have been incredibly fortunate to have wonderful mentors, and I owe this achievement to them. I am grateful for the recognition and support from ASCO and would like to congratulate my esteemed colleagues who were also recognized with FASCO designation.”
Since joining SMHS in 2017, Goyal has helped expand the GW Cancer Center’s clinical capabilities in radiation oncology and has contributed to improvements in clinical operations and translational research. His clinical practice includes the use of advanced radiation techniques such as intensity-modulated radiation therapy, stereotactic radiosurgery, stereotactic body radiotherapy, and brachytherapy to treat patients with primary and metastatic solid tumors.
